Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sino BiopharmaceuticalSBMFF -0.84%56 Equity-to-Asset is 0.56 as of Jun. 2026, which is 27% above its 10-year median of 0.44. GuruFocus rates SBMFF with a GF Score™ of 56/100 and a GF Value™ of $0.68 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,410 Biotechnology companies, Sino Biopharmaceutical ranks worse than 74.47% on this metric.
Sino Biopharmaceutical (OTCPK:SBMFF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Sino Biopharmaceutical Equity-to-Asset Related Terms
Sino Biopharmaceutical Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Sino Biopharmaceutical's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SBMFF vs VRTX, REGN, MRNA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Sino Biopharmaceutical's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sino Biopharmaceutical Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Sino Biopharmaceutical's Equity-to-Asset falls into.
Sino Biopharmaceutical Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Sino Biopharmaceutical's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sino Biopharmaceutical (SBMFF) has a Equity-to-Asset of 0.56 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Sino Biopharmaceutical and its competitors. This is 27% above median its historical median of 0.44. Over the past decade, Sino Biopharmaceutical's Equity-to-Asset has ranged from 0.36 to 0.50. According to the industry distribution chart, Sino Biopharmaceutical ranks #1050 out of 1410 companies in the Biotechnology industry, placing it in the top 74.5%.
Is Sino Biopharmaceutical's Equity-to-Asset too high?
Sino Biopharmaceutical's current Equity-to-Asset of 0.56 is 27% above median its 10-year median of 0.44. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 0.50. The Biotechnology industry median Equity-to-Asset is 0.69. Sino Biopharmaceutical's value of 0.56 is 18.8% below this industry median. Based on the distribution chart, Sino Biopharmaceutical ranks #1050 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sino Biopharmaceutical has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sino Biopharmaceutical ranks #1050 out of 1410 companies for Equity-to-Asset. This places Sino Biopharmaceutical in the lower half of its industry. The industry median Equity-to-Asset is 0.69. Sino Biopharmaceutical's value of 0.56 is 18.8% below this benchmark. Historically, Sino Biopharmaceutical's own Equity-to-Asset has ranged from 0.36 to 0.50 over the past decade. While the company's 10-year median is 0.44 vs. the industry median of 0.69, Sino Biopharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sino Biopharmaceutical's current Equity-to-Asset of 0.56 is 18.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Sino Biopharmaceutical and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sino Biopharmaceutical's current Equity-to-Asset is 0.56, which is 27% above median its own 10-year median of 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (SBMFF) is currently considered Fairly Valued. The stock's GF Value™ is $0.68, compared to a current price of $0.70 — trading 2.2% above its estimated fair value. The current Equity-to-Asset is 0.56, which is 27% above median its 10-year median of 0.44 and 18.8% below the Biotechnology industry median of 0.69. Sino Biopharmaceutical's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Sino Biopharmaceutical (SBMFF), the current Equity-to-Asset is 0.56 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sino Biopharmaceutical (SBMFF) Overvalued in 2026?
Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be overvalued.
The current stock price of $0.70 is trading 2.2% above its estimated GF Value™ of $0.68.
GuruFocus considers Sino Biopharmaceutical to be Fairly Valued.
Key valuation signals for SBMFF:
Equity-to-Asset: 0.56 (27% above median its 10-year median of 0.44)
GF Value™: $0.68 vs. price of $0.70 (2.2% above fair value)
Industry Position: 18.8% below the Biotechnology median (#1050 of 1410)
No single metric tells the full story. See the SBMFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sino Biopharmaceutical Ltd is a Hong Kong-listed pharmaceutical company and one of China's largest drugmakers. It develops, manufactures, and sells both generic and innovative medicines, organized around therapeutic areas including oncology, hepatology, surgery and analgesics, and autoimmune and respiratory diseases. Its product portfolio spans small-molecule drugs, biologics, and traditional Chinese medicine injections, with oncology and other innovative therapies forming a growing share of revenue as the company shifts away from reliance on generics. The company sells primarily to hospitals, medical institutions, and distributors across mainland China, with limited international operations. Revenue comes mainly from pharmaceutical product sales, supplemented by licensing and collaboration arrangements. Sino Biopharmaceutical invests heavily in research and development and holds stakes in several biotech affiliates, and it competes with domestic peers such as Hengrui Pharmaceuticals and Hutchmed in the Chinese market.
56GF Score
Get the complete analysis for SBMFF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBMFF has been successfully added to your 
